Nexentis Technologies Inc (NXTS)

Nexentis Technologies Inc. is an Israel-based company incorporated in 2009 and listed on NASDAQ under the symbol NXTS as common stock. The company develops and operates an AI- and data-driven computational biotech platform focused on mitochondrial biology, precision oncology, and inflammatory metabolic diseases. Its biotechnology segment uses the proprietary MITOLINE discovery engine and structure-guided virtual screening methods to identify small-molecule therapeutics targeting the mitochondrial SLC25 carrier family, with preclinical programs aimed at resistant cancers and metabolic-inflammation indications. Nexentis has also reported evidence of anti-tumor and anti-inflammatory activity in human-relevant systems. Beyond biotechnology, the company manages non-core renewable energy investments, including solar energy projects across multiple European Union countries through a ready-to-build model, and provides post-harvest treatment technologies designed to reduce pathogen contamination in fruits and vegetables. The company serves customers in biotechnology, pharmaceuticals, renewable energy, and agriculture, with operations centered in the European Union and Israel. Formerly known as N2OFF, Inc., it adopted its current name in February 2026.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.